The number of new graduates hired for sales rep roles increased in FY2025 after declining for five consecutive years, a…
BUSINESS
Fujifilm Wants to Launch Avigan Trial in Japan by End of This Week, Abe Talks to WHO Chief
Fujifilm Toyama Chemical plans to kick off its company-sponsored registration trial in Japan for the anti-flu agent Avigan (favipiravir) by the end of the week at the earliest for the treatment of the novel coronavirus disease COVID-19, a company official…
To read the full story
Related Article
- Kato Repeats May-End Goal for Avigan OK, Negative for Use in Mildly Ill Patients
May 11, 2020
- Japan Eyes May Approval for Avigan with Investigator-Led Study Data
May 7, 2020
- Japan Can’t Give “Special Approval” for Avigan under Current Law: Abe
April 30, 2020
- Fujifilm Starts Boosting Avigan Production for COVID-19
April 16, 2020
- Fujifilm to Start PII Avigan Trial for COVID-19 in US
April 10, 2020
- Fujifilm Launches Avigan Trial with Completion Eyed in June; Sanofi Too to Test Kevzara in Japan
April 1, 2020
- PM Abe Says Japan to Start Registration Trial for Avigan for COVID-19, Plans Production Boost
March 30, 2020
- Japan Plans Alvesco Clinical Trial for Coronavirus
March 24, 2020
- Japan’s Avigan Stockpile for Some 2 Million People; No Plan for Increase: Govt
March 18, 2020
- Fujifilm Plans Company-Sponsored Avigan Trial for COVID-19 in Japan
March 17, 2020
- Fujifilm Receives Avigan Supply Requests from Overseas amid Coronavirus Outbreak
February 27, 2020
BUSINESS
- Fujifilm Seeks Japan Nod for Stem Cell Therapy for Meniscus Injuries
May 15, 2025
- Tecentriq Filed for Thymic Carcinoma in Japan: Chugai
May 15, 2025
- Chugai’s DMD Gene Therapy Snags Conditional Approval in Japan
May 14, 2025
- Sumitomo Charts Revival Plan, Eyes 250 Billion Yen with 3 Key Meds by FY2027
May 14, 2025
- Suzuken Forms Tie-Up with Dongwon Group in South Korea
May 14, 2025
The traditional HR Business Partner (HRBP) model, once the gold standard for HR delivery, is undergoing a significant transformation. Many organizations, particularly in industries like pharmaceuticals, are moving towards a more agile resource model, aiming to streamline HR operations and…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…